Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.52 |
| ▸ | NOD1 | Q9Y239 | 7/20 | 0.44 |
| ▸ | TLR2 | O60603 | 2/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
| ▸ | ALB | P02768 | 1/20 | 0.38 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14903000 | 0.86 | GLP1R (0.49) | GLP1RNOD1TLR2SIRT2ALB | |
| SCHEMBL45887 | 0.86 | GLP1R (0.57) | GLP1RNOD1TLR2SIRT2ALB | |
| SCHEMBL45885 | 0.84 | GLP1R (0.56) | GLP1RNOD1TLR2SIRT2ALB | |
| SCHEMBL16525843 | 0.84 | GLP1R (0.56) | GLP1RNOD1TLR2SIRT2ALB | |
| SCHEMBL25604609 | 0.84 | GLP1R (0.46) | GLP1RNOD1TLR2SLC6A5 | |
| SCHEMBL14902999 | 0.83 | GLP1R (0.46) | GLP1RNOD1TLR2SIRT2ALB | |
| SCHEMBL25454947 | 0.81 | TLR2 (0.39) | GLP1RNOD1TLR2SIRT2ALB | |
| SCHEMBL20366283 | 0.80 | NOD1 (0.61) | GLP1RNOD1SLC6A5 | |
| SCHEMBL19224366 | 0.80 | GLP1R (0.51) | GLP1RNOD1TLR2SIRT2ALB | |
| SCHEMBL13753618 | 0.80 | GLP1R (0.51) | GLP1RNOD1TLR2SIRT2ALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11766414-B2 | Compositions, delivery systems, and methods useful in tumor therapy | INDI MOLECULAR, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20220211648-A1 | COMPOSITIONS, DELIVERY SYSTEMS, AND METHODS USEFUL IN TUMOR THERAPY | INDI MOLECULAR, INC. | 2022-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11766414-B2 | Compositions, delivery systems, and methods useful in tumor therapy | TP53, BAX, RNASE1 | GLP1R 4422/4885NOD1 2342/4885TLR2 1587/4885 |
| US-20220211648-A1 | COMPOSITIONS, DELIVERY SYSTEMS, AND METHODS USEFUL IN TUMOR THERAPY | TP53, BAX, RNASE1 | GLP1R 4422/4885NOD1 2342/4885TLR2 1587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.